Quality of life with first-line ribociclib plus endocrine therapy vs combination chemotherapy in clinically aggressive HR+/HER2− ABC: RIGHT Choice

BACKGROUND: The RIGHT Choice phase 2 randomized clinical trial of pre/perimenopausal women with clinically aggressive hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC) reported a statistically significant progression-free survival benefit with ribociclib plus endocrine therapy (ET) over combination chemotherapy (21.8 vs 12.8 months; HR, 0.61; 95% CI: 0.43-0.87; P = .003), with lower rates of symptomatic adverse events. This prespecified analysis compared QOL outcomes between treatment arms in RIGHT Choice to support treatment decision-making in these patients. PATIENTS AND METHODS: Pre/perimenopausal women with clinically aggressive HR+/HER2- ABC were randomized 1:1 to first-line ribociclib plus letrozole/anastrozole/goserelin or investigator's choice of combination chemotherapy. Median time to definitive deterioration (mTTDD) from randomization in Functional Assessment of Cancer Therapy-Breast (FACT-B) scores (≥10%) or a composite mTTDD endpoint (including treatment discontinuation) was determined by Kaplan-Meier methods. RESULTS: mTTDD in FACT-B overall health status, trial outcome index (TOI), and nausea scores was prolonged in patients receiving ribociclib plus ET versus combination chemotherapy (HR, 0.72, 0.63, and 0.59, respectively), while the pain score was similar between treatment arms (HR, 1.05). The composite mTTDD in overall health status, TOI, pain, and nausea scores was longer in patients in the ribociclib arm (HR, 0.68, 0.65, 0.76, and 0.62, respectively). CONCLUSIONS: Treatment with first-line ribociclib plus ET translates into improved QOL versus combination chemotherapy in patients with clinically aggressive HR+/HER2- ABC. These data reinforce efficacy and safety findings supporting cyclin-dependent kinase 4 and 6 inhibitors plus ET as the preferred option in this population. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT03839823.

Authors

Institutions

Publication Details

Journal
The Oncologist
Published
2026-11-18
DOI
https://doi.org/10.1093/oncolo/oyag447
Primary Topic
Advanced Breast Cancer Therapies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Quality of life with first-line ribociclib plus endocrine therapy vs combination chemotherapy in clinically aggressive HR+/HER2− ABC: RIGHT Choice

Ghislaine Vincent, Mélissa Gao, Hikmat Abdel‐Razeq, Nagi S. El Saghir et al.
The Oncologist
Advanced Breast Cancer Therapies
article

Quality of life with first-line ribociclib plus endocrine therapy vs combination chemotherapy in clinically aggressive HR+/HER2− ABC: RIGHT Choice

Ghislaine Vincent, Mélissa Gao, Hikmat Abdel‐Razeq, Nagi S. El Saghir, Yoon Sim Yap, Yogesh Chattar, Seock‐Ah Im, Naiyarat Prasongsook, Lyudmila Zhukova, Jiwen Wu, Hamdy A. Azim, Julie Rihani, Yeşim Eralp, Yen-Shen Lu
article en

Abstract

BACKGROUND: The RIGHT Choice phase 2 randomized clinical trial of pre/perimenopausal women with clinically aggressive hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC) reported a statistically significant progression-free survival benefit with ribociclib plus endocrine therapy (ET) over combination chemotherapy (21.8 vs 12.8 months; HR, 0.61; 95% CI: 0.43-0.87; P = .003), with lower rates of symptomatic adverse events. This prespecified analysis compared QOL outcomes between treatment arms in RIGHT Choice to support treatment decision-making in these patients. PATIENTS AND METHODS: Pre/perimenopausal women with clinically aggressive HR+/HER2- ABC were randomized 1:1 to first-line ribociclib plus letrozole/anastrozole/goserelin or investigator's choice of combination chemotherapy. Median time to definitive deterioration (mTTDD) from randomization in Functional Assessment of Cancer Therapy-Breast (FACT-B) scores (≥10%) or a composite mTTDD endpoint (including treatment discontinuation) was determined by Kaplan-Meier methods. RESULTS: mTTDD in FACT-B overall health status, trial outcome index (TOI), and nausea scores was prolonged in patients receiving ribociclib plus ET versus combination chemotherapy (HR, 0.72, 0.63, and 0.59, respectively), while the pain score was similar between treatment arms (HR, 1.05). The composite mTTDD in overall health status, TOI, pain, and nausea scores was longer in patients in the ribociclib arm (HR, 0.68, 0.65, 0.76, and 0.62, respectively). CONCLUSIONS: Treatment with first-line ribociclib plus ET translates into improved QOL versus combination chemotherapy in patients with clinically aggressive HR+/HER2- ABC. These data reinforce efficacy and safety findings supporting cyclin-dependent kinase 4 and 6 inhibitors plus ET as the preferred option in this population. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT03839823.

The Oncologist
Novartis (Switzerland) (CH), Cairo University (EG), Cancer Research Institute (US), King Hussein Cancer Center (JO), Seoul National University Hospital (KR), Moscow Clinical Scientific Center (RU), Phramongkutklao Hospital (TH), American University of Beirut Medical Center (LB), Novartis (United States) (US), National Taiwan University Hospital (TW), National Cancer Centre Singapore (SG)
Advanced Breast Cancer Therapies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon